List view / Grid view
14 May 2015 | By Victoria White
First AF patient is enrolled in a study assessing the safety and efficacy of uninterrupted anticoagulation with dabigatran during ablation procedures...
14 May 2015 | By Victoria White
A US initiative to get doctors to stop using interventions with no benefit, Choosing Wisely, is being launched in the UK this week...
14 May 2015 | By Victoria White
Results from two pivotal studies have shown that alectinib shrank tumours in people with advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC)...
14 May 2015 | By Victoria White
Jim O’Neill’s Review on Antimicrobial Resistance sets out proposals to overhaul the global antibiotics pipeline over the next ten years...
13 May 2015 | By Victoria White
Pharma and medical supply companies have been earmarked by HMRC as a potential target for VAT fraud, but many are not yet attuned to the risk...
13 May 2015 | By Victoria White
The treatment market value for fibromyalgia across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, will expand from $1.8 billion in 2013 at a tepid Compound Annual Growth Rate (CAGR) of 0.72% to reach $1.9 billion by 2023, according to research and consulting…
13 May 2015 | By Cherwell Laboratories
Company focus on operational enhancements and maintenance of core values...
13 May 2015 | By Victoria White
EIB has reaffirmed its commitment to respond to the Ebola pandemic by providing a EUR 50m loan to Bavarian Nordic for accelerated development of a vaccine...
13 May 2015 | By Victoria White
Businesses, including those in the pharmaceutical sector, should start assessing the potential consequences of a Brexit, advises Hogan Lovells...
13 May 2015 | By Victoria White
Results from a Phase 3 study of the liquid-frozen formulation of IMVAMUNE support a Biologics License Application for US approval of the vaccine...
13 May 2015 | By Victoria White
CPhI Worldwide has launched a new partnership with charity Global Angels to help promote its efforts and encourage support from the pharmaceutical industry....
13 May 2015 | By
Actavis has responded to the decision by the SMC to accept Ozurdex for use by NHS Scotland for the treatment of visual impairment in patients with DMO...
Baxter has signed a definitive agreement to acquire the Oncaspar® (pegaspargase) product portfolio from Sigma-Tau for US $900 million.
12 May 2015 | By Victoria White
Highland Therapeutics has announced that it will host a poster presentation highlighting Phase III clinical data for its ADHD treatment at APA 2015...
12 May 2015 | By Victoria White
GBI Research reports on the highly diverse and innovative pipeline for Duchenne Muscular Dystrophy and Becker Muscular Dystrophy treatment...
